2019
DOI: 10.29271/jcpsp.2019.04.400
|View full text |Cite
|
Sign up to set email alerts
|

Preventive Effect of Somatostatin on Pancreatitis and Hyperamylasemia after Therapeutic ERCP

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 5 publications
(5 reference statements)
0
0
0
Order By: Relevance
“…Somatostatin is a synthetic peptide hormone with a half-life period of less than 3 minutes. It has been proven to have a good therapeutic effect in the treatment of digestive system diseases such as acute pancreatitis and esophageal variceal bleeding [10,11]. Recently, SOM has been shown to have inhibitory effects in various cancers, including prostate cancer [12], medullary thyroid cancer [13], gastric cancer [14], and PC [15].…”
Section: Discussionmentioning
confidence: 99%
“…Somatostatin is a synthetic peptide hormone with a half-life period of less than 3 minutes. It has been proven to have a good therapeutic effect in the treatment of digestive system diseases such as acute pancreatitis and esophageal variceal bleeding [10,11]. Recently, SOM has been shown to have inhibitory effects in various cancers, including prostate cancer [12], medullary thyroid cancer [13], gastric cancer [14], and PC [15].…”
Section: Discussionmentioning
confidence: 99%